Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

about

Accurate assessment of HER2 gene status for invasive component of breast cancer by combination of immunohistochemistry and chromogenic In Situ hybridization.

Item

http://www.wikidata.org/entity/Q46565660

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@en

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@nl

type

Item

label

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@en

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@nl

prefLabel

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@en

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@nl

P1476

Accurate assessment of HER2 ge ...... mogenic In Situ hybridization.

@en

P2093

Chun-ping Liu

http://www.w3.org/2001/XMLSchema#string

Dan-zhen Pan

http://www.w3.org/2001/XMLSchema#string

Hua-xiong Pan

http://www.w3.org/2001/XMLSchema#string

Jun He

http://www.w3.org/2001/XMLSchema#string

Mi-xia Weng

http://www.w3.org/2001/XMLSchema#string

Tao Huang

http://www.w3.org/2001/XMLSchema#string

Xiu Nie

http://www.w3.org/2001/XMLSchema#string

Xiu-ping Yang

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

P2860

Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens

Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization.

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Chromogenic and fluorescent in situ hybridization in breast cancer.

Emerging technologies for assessing HER2 amplification.

Role of axillary staging in women diagnosed with ductal carcinoma in situ with microinvasion.

Current practical applications of diagnostic immunohistochemistry in breast pathology.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P2888

s11596-013-1128-5

P304

379-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11596-013-1128-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23771664

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry